Your session is about to expire
← Back to Search
Nicotinamide riboside for COVID-19 (NIRVANA Trial)
NIRVANA Trial Summary
This trial will use NR to see if it can help improve NAD+ levels in people with COVID-19 and acute kidney injury. They will also be looking at the safety of using NR.
- COVID-19
- Acute Kidney Injury
NIRVANA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNIRVANA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NIRVANA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the ultimate objective of this research endeavor?
"This trial, lasting 10 days from the Baseline measurement, is targeting a Change in whole blood NAD+ level. Additional objectives include measuring changes to AUC serum creatinine over this period of time, Proteinuria at 30-90 days post randomization and eGFR also at 30-90 days post randomization."
Has Nicotinamide riboside received regulatory clearance from the FDA?
"The safety of Nicotinamide riboside was provisionally rated a 2, as there is some evidence in favour of its security profile but no proof yet that it works."
Are there any prior experiments with Nicotinamide riboside that have yielded noteworthy results?
"Presently, there are 23 clinical trials for Nicotinamide riboside that have commenced. Of these active studies, 3 of them fall into the Phase 3 category. Most experiments take place in Philadelphia; however, 26 different sites across the country host their own research initiatives related to this medication."
Are participants in this study still being recruited?
"According to the information stored on clinicaltrials.gov, this particular trial is currently not open for recruitment. Initially posted on June 11th 2021 and lastly updated October 25th 2022, it has since been superseded by 1188 other medical studies actively requesting participants."
What is the aggregate quantity of individuals engaging in this clinical experiment?
"Unfortunately, no new participants are being accepted into this trial at present. The posting of the study was first noted on June 11th 2021 and it has been updated most recently on October 25 2022. If you require further information about other clinical trials, there are currently 1165 studies recruiting for acute kidney injury and 23 involving Nicotinamide riboside seeking out patients."
Share this study with friends
Copy Link
Messenger